Penumbra/$PEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Penumbra
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
Ticker
$PEN
Sector
Primary listing
NYSE
Employees
4,700
Headquarters
Website
Penumbra Metrics
BasicAdvanced
$13B
73.09
$4.52
0.81
-
Price and volume
Market cap
$13B
Beta
0.81
52-week high
$362.41
52-week low
$221.26
Average daily volume
666K
Financial strength
Current ratio
6.644
Quick ratio
4.013
Long term debt to equity
14.252
Total debt to equity
15.389
Interest coverage (TTM)
144.35%
Profitability
EBITDA (TTM)
206.52
Gross margin (TTM)
67.14%
Net profit margin (TTM)
12.66%
Operating margin (TTM)
13.48%
Effective tax rate (TTM)
13.38%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
7.04%
Return on equity (TTM)
13.78%
Valuation
Price to earnings (TTM)
73.088
Price to revenue (TTM)
9.16
Price to book
9.08
Price to tangible book (TTM)
10.33
Price to free cash flow (TTM)
73.497
Free cash flow yield (TTM)
1.36%
Free cash flow per share (TTM)
4.495
Growth
Revenue change (TTM)
17.50%
Earnings per share change (TTM)
1,155.56%
3-year revenue growth (CAGR)
18.33%
10-year revenue growth (CAGR)
22.39%
3-year earnings per share growth (CAGR)
340.44%
10-year earnings per share growth (CAGR)
49.69%
What the Analysts think about Penumbra
Analyst ratings (Buy, Hold, Sell) for Penumbra stock.
Penumbra Financial Performance
Revenues and expenses
Penumbra Earnings Performance
Company profitability
Penumbra News
AllArticlesVideos
Boston Scientific to acquire Penumbra in $14.5B deal
Proactive Investors·3 months ago
Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion.
Barrons·3 months ago
Boston Scientific is buying Penumbra for $14.5 billion, gaining entry to ‘fast-growing' vascular segments
Market Watch·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Penumbra stock?
Penumbra (PEN) has a market cap of $13B as of April 04, 2026.
What is the P/E ratio for Penumbra stock?
The price to earnings (P/E) ratio for Penumbra (PEN) stock is 73.09 as of April 04, 2026.
Does Penumbra stock pay dividends?
No, Penumbra (PEN) stock does not pay dividends to its shareholders as of April 04, 2026.
When is the next Penumbra dividend payment date?
Penumbra (PEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Penumbra?
Penumbra (PEN) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.